The current study revealed that NFκB overexpression is a negative prognosticator of LPFS, DMFS, and OS, whereas expression of p16 is inversely associated with LPFS in patients with bladder cancer undergoing trimodality bladder-preserving therapy. Here, NFKB1 is linked to urinary bladder carcinoma.